Nevro (NYSE: NVRO) is a public multinational medical technology company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has impacted the lives of over 28,000 patients around the world.
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
The market access team is focused on ensuring all patients have access to HF10 therapy. There are a number of different areas we work in to achieve this: working with payers (Medicare and commercial payers) to ensure coverage and recognition of HF10, partnering with customers to allow access at facilities, pricing strategy, health economics initiatives and focusing on the product pipeline and future coverage.
The 2018 Market Access intern will work across a number of these initiatives. He/she will report directly to the Director of Market Access and support projects regarding payer coverage, health economics analyses and reimbursement support for customers. Two key projects would include analyses of reimbursement and payer coverage for future product indications and a customer value analysis.